Results 221 to 230 of about 744,991 (311)

Single‐Cell Transcriptomics Reveals FLS2‐Dependent Hypoxia Signaling and ERF13‐Mediated Transcription During flg22‐Triggered Immunity

Advanced Science, EarlyView.
This study employs sc‐RNA sequencing, genetics, and phenotyping to systematically map the cell‐type‐specific immune responses triggered by flg22. It reveals FLS2‐dependent transcriptional reprogramming in epidermal and mesophyll cells, and uncovers crosstalk between immune and hypoxia signaling pathways.
Yaping Zhou, Aizhi Qin, Mengfan Li, Qianli Zhao, Luyao Kong, Lulu Yan, Chunyang Li, Hao Liu, Yinpeng Zhang, Jiani Long, Mengyu Liao, Mengmeng Zhou, Xiaoli Fan, Baozhen Wang, Wenxuan Kang, Shui Wang, Zhixin Liu, Xuwu Sun   +17 more
wiley   +1 more source

The emerging role of TLR7-mediated signaling in respiratory viral infections and autoimmune diseases. [PDF]

Cell Mol Life Sci
Wang C, Evangelista JF, Vidal AKN, Islamuddin M, Chen Y, Xu D, Qin X.   +6 more
europepmc   +1 more source

PET Imaging of Cardiac Inflammation in Viral Myocarditis Using a DPP4‐Targeted Probe

Advanced Science, EarlyView.
This study describes a DPP4‐targeted PET probe for imaging myocardial inflammation by selectively targeting activated immune cells. Derived from the clinically approved small‐molecule inhibitor linagliptin, the probe demonstrates favorable biodistribution with specific cardiac uptake in myocarditis.
Wanhao Gao, Wenzhu Hu, Du Tang, Xinxin Liu, Kun Yu, Lixia Feng, Minyu Liao, Wang Lin, Wenqiang Zhu, Sanjay Rajagopalan, Xiaoli Lan, Jixin Zhong, Dao Wen Wang, Dawei Jiang, Xiaoquan Rao   +14 more
wiley   +1 more source

Extracellular Vesicles in Autoimmune Diseases: From Diagnostic Biomarkers to Engineered Therapeutics. [PDF]

Adv Sci (Weinh)
Wu Y, Ma H, Zhu T, Huang S, Lu M, Wang Q, Chi ZL.   +6 more
europepmc   +1 more source

GPCRs in CAR‐T Cell Immunotherapy: Expanding the Target Landscape and Enhancing Therapeutic Efficacy

Advanced Science, EarlyView.
Chimeric antigen receptor T cell therapy faces dual challenges of target scarcity and an immunosuppressive microenvironment in solid tumors. This review highlights how G protein‐coupled receptors can serve as both novel targets to expand the therapeutic scope and functional modules to enhance CAR‐T cell efficacy.
Zhuoqun Liu, Yuchen Xiao, Yamin Zhao, Lihe Dai, David J.H. Shih, Shikang Liang, Honglei Tian, Liu Liu, Feng Tian, Bing Liu, Lei Chang, Chao Zhang   +11 more
wiley   +1 more source

Annexins and autoantibodies in autoimmune diseases - Insights into SLE, APS and RA: A review.

Biomol Biomed
Zhou X, Liu J, Wang S, Zhang Y, Xu L, Wu L.   +5 more
europepmc   +1 more source

CAR-T and BiTE: new horizons in the treatment of rheumatic autoimmune diseases. [PDF]

Front Immunol
Li J, Guo Q, Li L, Wang J, Zhang L.
europepmc   +1 more source

Depletion of the RNA‐Editing Enzyme ADAR1 Invigorates the Antitumor Immunity of NK Cells

Advanced Science, EarlyView.
ADAR1 is upregulated in NK cells from melanoma patients, impairing their function. Its loss enhances NK cell tumor infiltration and cytotoxicity in vitro and in vivo. Mechanistically, ADAR1 deficiency destabilizes CD38 mRNA to reduce its expression, thereby increasing NK cell mobility and killing, which nominates it as a therapeutic target for NK cell ...
Shuhan Chen, Di Lu, Rukang Liang, Weikeng Tan, Erming Zhao, Sihuang Wu, Xintong Li, Yulong Song, Miaojian Wan, Xiaoyuan Xie, Qi Zhang, Qiuli Liu   +11 more
wiley   +1 more source

Artificial intelligence in immunotherapy: revolutionizing diagnostic and therapeutic applications in cancer and autoimmune diseases. [PDF]

Clin Exp Med
Alshorman J, Mehran MJ, Bahrami Y, Mohammadzadeh S, Barzigar R, Morshedi M, Haider KH, Tembo KM, Rong SJ, Jadgal N, Altahla R, Bolideei M, Wang Y.   +12 more
europepmc   +1 more source

Beyond CD30: Dual‐Targeting of Malignant and Regulatory T Cells by Brentuximab Vedotin Remodels the Lymphoma Microenvironment and Overcomes Resistance via BCL2 Inhibition in Mycosis Fungoides

Advanced Science, EarlyView.
Single‐cell RNA analyses of paired lesions from CD30+ mycosis fungoides patients demonstrate that brentuximab vedotin (BV) induces immunogenic cell death in both CD30+ and CD30− malignant T cells. BV also targets regulatory T cells and remodels tumor microenvironment, while resistance is driven by impaired IFN responses, drug efflux, and BCL2 ...
Yi Jiang, Pan Lai, Mingjia Li, Yujie Wen, Mengzhou Cao, Yu Xiao, Zhuojing Chen, Jingru Sun, Yang Wang   +8 more
wiley   +1 more source